John Sfakianos, MD, Associate Professor of Urology and Urologic Oncology at the Icahn School of Medicine at Mount Sinai, shares insights on mechanism behind Bacillus Calmette-Guerin (BCG) resistance in situ non–muscle-invasive bladder cancer (NMIBC). Learn more: https://lnkd.in/eyBv5wkK
Mount Sinai Innovation Partners
医院和医疗保健
New York,NY 5,750 位关注者
Bringing the Mount Sinai Health System's discoveries to life
关于我们
Mount Sinai Innovation Partners (MSIP), the technology commercialization arm of the Mount Sinai Health System, facilitates the transfer of discovery from the laboratory to the marketplace, acting as the interface with commercial entities. MSIP is responsible for the full spectrum of commercialization activities required to bring Mount Sinai's inventions to life. These activities include evaluating, patenting, marketing, and licensing new technologies, while also negotiating agreements for sponsored research, material transfer, and confidentiality.
- 网站
-
https://ip.mountsinai.org/
Mount Sinai Innovation Partners的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 51-200 人
- 总部
- New York,NY
- 类型
- 非营利机构
- 领域
- technology transfer、startups、intellectual property management、licensing、healthcare、medical innovation、education、research innovation、technology development、commercialization、entrepreneurship和accelerator
地点
-
主要
150 East 42nd St.
2nd Floor
US,NY,New York,10017
Mount Sinai Innovation Partners员工
动态
-
Climate change can make migraines even worse. But how? Researchers, including Fred Cohen, MD, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai, weigh in with WIRED on the connection between these severe headaches and rising temperatures: https://lnkd.in/eG2incqt
The Multiple Ways Climate Change Threatens to Make Migraines Worse
wired.com
-
Explore the MSIN site! Our mission is to discover and develop leading-edge innovations! Connect with us today to learn more about specific research, technologies, and opportunities. https://lnkd.in/eX6xnvAQ
-
-
R&D company IPGaia and the Icahn School of Medicine at Mount Sinai are collaborating to enhance drug discovery efforts, with the goal of developing new medicines and healthcare solutions with greater efficiency. Learn more: https://lnkd.in/eHupGTBw
IPGaia and the Icahn School of Medicine at Mount Sinai Announce Comprehensive Collaborative Research and Development Agreement - Mount Sinai Innovation Partners
https://ip.mountsinai.org
-
Have you met this year's Mount Sinai Pitch Challenge winners? Get to know the technologies that took home first place at MSIP's annual competition, each led by researchers from the Icahn School of Medicine at Mount Sinai! https://lnkd.in/eejVRWi6
ip.mountsinai.org/blog/msips-ent…
https://ip.mountsinai.org
-
Have you met this year's Mount Sinai Pitch Challenge winners? Discover their solutions that cover different healthcare fields, all with the goal of helping patients! You'll also learn exciting updates about MSIP's Entrepreneurship Program. https://lnkd.in/eejVRWi6
MSIP’s Entrepreneurship Updates: Pitch Challenge Winners, Upcoming Program Dates, and More - Mount Sinai Innovation Partners
https://ip.mountsinai.org
-
Steven A. Kaplan, MD, Professor of Urology at the Icahn School of Medicine at Mount Sinai, shares findings from a phase 1 study of ASP-001, an investigational oral formulation of sildenafil for patients with erectile dysfunction. Learn more: https://lnkd.in/e4XVp67z
Steven A. Kaplan, MD, shares initial data on sildenafil oral spray vs tablets
urologytimes.com
-
Robert Rosenson, MD, from the Icahn School of Medicine at Mount Sinai, discusses his research regarding the use of the drug zodasiran (formerly ARO-ANG3), targeting triglycerides and other lipoprotein levels. Learn more: https://lnkd.in/eQmBVxGB
Gene Silencing Benefit of Zodasiran in Hyperlipidemia
medscape.com
-
“We look forward to working with IPGaia, enhancing efforts in drug discovery and addressing healthcare challenges. Their innovative platform will contribute to our shared goals in advancing early stage biomedical research.” -Erik Lium, PhD, the Chief Commercial Innovation Officer at the Mount Sinai Health System and President of MSIP. The Icahn School of Medicine at Mount Sinai and research & development company IPGaia have established a framework that aims to develop drug targets to be licensed to pharma companies for advancement to patients. Learn more: https://lnkd.in/eHupGTBw
-
-
Explore the MSIN site! Our mission is to discover and develop leading-edge innovations! Connect with us today to learn more about specific research, technologies, and opportunities. https://lnkd.in/eX6xnvAQ
-